Molecular Measurable Residual Disease Assessment before Hematopoietic Stem Cell Transplantation in Pediatric Acute Myeloid Leukemia Patients: A Retrospective Study by the I-BFM Study Group

Molecular Measurable Residual Disease Assessment before Hematopoietic Stem Cell Transplantation in Pediatric Acute Myeloid Leukemia Patients: A Retrospective Study by the I-BFM Study Group

Hematopoietic stem cell transplantation (HSCT) is a curative post-remission treatment in patients with acute myeloid leukemia (AML), but relapse after transplant is still a challenging event. In recent year, several studies have investigated the molecular minimal residual disease (qPCR-MRD) as a pre...

Full description

Bibliographic Details
Main Authors: Abrahamsson, J. (Author), Benetton, M. (Author), Da Ros, A. (Author), Fogelstrand, L. (Author), Hansen, M. (Author), Hasle, H. (Author), Locatelli, F. (Author), Merli, P. (Author), Pigazzi, M. (Author), Polato, K. (Author), Reinhardt, D. (Author), Sonneveld, E. (Author), Strocchio, L. (Author), Tregnago, C. (Author), Von Neuhoff, N. (Author), Walter, C. (Author)
Format: Article
Language:English
Published: MDPI 2022
Subjects:
AML
HSCT
molecular genetics
MRD
q-PCR
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items